SCHEMBL5142268

SCHEMBL5142268

O=C(O)c1ccc(Oc2cc[c]cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 3/20 0.62
PARP15 Q460N3 2/20 0.62
SRD5A2 P31213 5/20 0.60
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
PARP14 Q460N5 1/20 0.48
PARP16 Q8N5Y8 1/20 0.48
PARP11 Q9NR21 1/20 0.48
PARP4 Q9UKK3 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL766069 0.87 PARP10 (0.78) PARP10PARP15SRD5A2CA1CA2
SCHEMBL22281 0.87 PARP10 (0.78) PARP10PARP15SRD5A2CA1CA2
SCHEMBL5581520 0.87 PARP10 (0.78) PARP10PARP15SRD5A2CA1CA2
Terephthalic Acid SCHEMBL9861713 0.87 PARP10 (0.78) PARP10PARP15SRD5A2CA1CA2
Hydrochloric Acid SCHEMBL2709951 0.84 PARP10 (0.75) PARP10PARP15SRD5A2CA1CA2
Ammonia Solution, Strong SCHEMBL9436485 0.84 PARP10 (0.75) PARP10PARP15SRD5A2CA1CA2
Hydrochloric Acid SCHEMBL5042789 0.84 PARP10 (0.75) PARP10PARP15SRD5A2CA1CA2
Hydrochloric Acid SCHEMBL9633355 0.84 PARP10 (0.75) PARP10PARP15SRD5A2CA1CA2
SCHEMBL5158928 0.83 SRD5A2 (0.55) PARP10PARP15SRD5A2TSHRKMT2A
Ethane SCHEMBL11219716 0.82 PARP10 (0.72) PARP10PARP15SRD5A2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105131289-A Novel sulfonated polybenzimidazole copolymer, crosslinked membrane, preparation method and application thereof UNIV SHANGHAI JIAOTONG 2015-12-09 CN claimed
CN-102219898-B Poly-schiff base for resistance-type storage material NINGBO INST MAT TECH & ENG CAS 2012-10-17 CN claimed
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP claimed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US claimed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO claimed
CN-109806912-B Neodymium complex/GO/Fe capable of being magnetically recycled3O4Ternary complex and preparation method and application thereof 山西大学 2021-05-14 CN disclosed
CN-104822444-B Gas separation membrane 中央硝子株式会社 2017-03-08 CN disclosed
CN-103561852-B Gas separation membrane CENTRAL GLASS CO.,LTD. (JP) 2016-03-30 CN disclosed
CN-103562261-B Fluoropolymer monomer and use its macromolecular compound CENTRAL GLASS CO.,LTD. (JP) 2016-03-16 CN disclosed
CN-105131289-A Novel sulfonated polybenzimidazole copolymer, crosslinked membrane, preparation method and application thereof UNIV SHANGHAI JIAOTONG 2015-12-09 CN disclosed
CN-104837809-A Diamine containing hexafluoroisopropanol group, polyimide and polyamide using the same, cyclized product thereof, and method for producing the same CENTRAL GLASS CO LTD 2015-08-12 CN disclosed
CN-104822445-A Gas separation membrane CENTRAL GLASS CO LTD 2015-08-05 CN disclosed
US-20030187042-A1 NR1H4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2003-10-02 US disclosed
WO-2003015771-A1 FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS LION BIOSCIENCE AG (DE) 2003-02-27 WO disclosed
US-5777151-A REACTING CARBOXYLIC ACID SALT WITH ORGANIC HALOCOMPOUND USING ONIUM SALT PHASE TRANSFER CATALYST RHONE-POULENC CHIMIE (FR) 1998-07-07 US disclosed
US-5260475-A Esterification of hydroxybenzoic acids RHONE-POULENC CHIMIE (FR) 1993-11-09 US disclosed
US-4098816-A HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS BEECHAM GROUP LIMITED (GB) 1978-07-04 US disclosed
US-4067892-A HYPOLIPIDEMIC, HYPOGLYCEMIC BEECHAM GROUP LIMITED (GB) 1978-01-10 US disclosed
US-4067892-A HYPOLIPIDEMIC, HYPOGLYCEMIC BEECHAM GROUP LIMITED (GB) 1978-01-10 US disclosed
US-3983164-A HYPOLIPOLYTIC AND HYPOGLYCEMIC AGENTS BEECHAM GROUP LIMITED (GB) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187042-A1 NR1H4 nuclear receptor binding compounds NR1H4, NR1H2, NR1H3 PARP10 1009/4885PARP15 1099/4885SRD5A2 113/4885
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases PTPRO, PTPRG, PTPN1 PARP10 4399/4885PARP15 4629/4885SRD5A2 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.